How do peptides work?
How do peptides work? These mechanism articles are the how behind the what. If you want to understand what a GLP-1 dual agonist actually does after injection, why a growth hormone peptide works with your pituitary instead of around it, or which receptor a molecule binds — this is that shelf.
Written to be understood like you're fifteen, sourced from the primary literature, and honest wherever the mechanism is still a hypothesis rather than settled science.
148 articles on this topic
-
Semaglutide and Intermittent Fasting: What We Know
No published randomized weight-loss trial has shown that intermittent fasting adds a benefit to semaglutide. The safest answer depends on diabetes medicines, side effects, hydration, and whether the eating window leaves enough room for nutrition.
-
Tesamorelin Clinical Trials: What the Studies Show
The large trials found less visceral abdominal fat in adults with HIV-associated lipodystrophy. They did not test general weight loss, anti-aging, or the compounded formulations sold today.
-
Who Discovered GHRH? The Two 1982 Teams
Two independent teams identified GHRH in 1982, using an unexpected clue from pancreatic tumors. Their papers opened the path to sermorelin, tesamorelin and CJC-1295.
-
Eloralintide Plus Tirzepatide: What the 17% Means
Lilly says adding its experimental amylin drug to a low dose of tirzepatide led to 17% weight loss in 16 weeks, against 10% on tirzepatide alone. Here is what that early number can and cannot tell you.
-
MOTS-c Exercise Claims: What the Studies Show
MOTS-c is called an exercise mimetic because exercise raises it in people and administered MOTS-c changed running performance in mice. No published human trial shows that taking it improves a workout.
-
Does Semaglutide Increase Heart Rate?
Yes, semaglutide can raise resting heart rate by a few beats per minute on average. A steady rise or a racing heartbeat at rest deserves a closer look, because an average cannot explain one person's symptoms.
-
Does Tirzepatide Cause Low Blood Sugar?
Tirzepatide can cause low blood sugar, but it was uncommon in trials of people without diabetes. The risk rises when insulin or a sulfonylurea is also part of treatment.
-
Who Discovered TB-500? The Full Story
The short answer starts with Teresa Low, Shu-Kuang Hu, and Allan Goldstein, who sequenced thymosin beta-4 in 1981. The seven-amino-acid fragment now called TB-500 came later, and the record does not name one inventor.
-
5 Percent Weight Loss Benefits: Study Numbers
Five percent can be a meaningful first milestone. Here's what studies measured in blood sugar, blood pressure, and sleep, and where the numbers stop being a useful prediction.
-
Who Discovered Kisspeptin? The People Behind It
Danny Welch's cancer research started the story in 1996. Other teams found the peptide, connected it to puberty, and brought it into human studies.
-
When Was Rybelsus Approved? September 20, 2019
Rybelsus was approved on September 20, 2019. The FDA letter marked the moment a GLP-1 medicine moved from injection-only treatment into a daily tablet.
-
BPC-157 Myths: 10 Claims Checked
Ten familiar claims about BPC-157, graded against the studies: what comes from rats, what has been observed in people, and what remains unknown.
-
Who Discovered MOTS-c? The 2015 USC Discovery
Changhan Lee, Pinchas Cohen, and their colleagues reported MOTS-c in 2015. Its history runs from an overlooked genetic sequence to human observations and an ongoing question about treatment.
-
Forzinity Approval: One Year Later
On September 19, 2025, Forzinity became the first treatment for Barth syndrome through accelerated approval. A year later, that narrow decision still rests on a required confirmatory trial.
-
BPC-157 Human Studies: What the Evidence Shows
Human evidence exists, but it is much smaller than online summaries make it sound: a few short, uncontrolled reports cannot establish that BPC-157 works or is safe long term.
-
Who Discovered GLP-1? The Team Behind the Medicine
No single scientist discovered GLP-1. The answer is a chain of teams that found the gene, identified the working hormone, tested what it did, and designed medicines that lasted long enough to use.
-
Kisspeptin Dose: What Human Studies Actually Used
There is no standard kisspeptin dose to copy from a study. Human trials used different peptide forms, routes, and schedules, so a prescription has to be set for the person and the clinical goal.
-
MOTS-c for Weight Loss: Human Evidence Is Thin
Mouse studies are interesting, but no completed randomized trial shows that MOTS-c causes weight loss in people. Human studies so far mostly measure the peptide already in the body.
-
MOTS-c Tablets: No Human Evidence Supports Them
MOTS-c tablets have no published human absorption data. The studies behind the peptide used injected animals or measured the MOTS-c people made themselves.
-
MOTS-c vs Tesamorelin: Not a Fat-Loss Contest
MOTS-c and tesamorelin work through different systems, and their evidence is not comparable. Tesamorelin has large late-stage trials for one narrow HIV-related condition; MOTS-c does not yet have completed human treatment results.
Page 1 of 8 · 148 articles